116 related articles for article (PubMed ID: 16738694)
1. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.
Pettitt AR; Matutes E; Oscier D
Leukemia; 2006 Aug; 20(8):1441-5. PubMed ID: 16738694
[No Abstract] [Full Text] [Related]
2. Alemtuzumab.
Williamson TS
Clin J Oncol Nurs; 2001; 5(6):287-8. PubMed ID: 11899633
[No Abstract] [Full Text] [Related]
3. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53.
Osuji NC; Del Giudice I; Matutes E; Wotherspoon AC; Dearden C; Catovsky D
Haematologica; 2005 Oct; 90(10):1435-6. PubMed ID: 16219582
[TBL] [Abstract][Full Text] [Related]
4. Taking the measure of alemtuzumab.
Gilleece MH
Leuk Res; 2004 Dec; 28(12):1253-4. PubMed ID: 15475064
[No Abstract] [Full Text] [Related]
5. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
[TBL] [Abstract][Full Text] [Related]
6. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
Cortelezzi A; Pasquini MC; Gardellini A; Gianelli U; Bossi A; Reda G; Sarina B; Musto P; Barcellini W; Neri A; Deliliers GL
Leukemia; 2009 Nov; 23(11):2027-33. PubMed ID: 19641526
[TBL] [Abstract][Full Text] [Related]
7. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Br J Haematol; 2009 Jan; 144(1):78-85. PubMed ID: 19016731
[TBL] [Abstract][Full Text] [Related]
9. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
[TBL] [Abstract][Full Text] [Related]
10. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC
Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone.
Kunz JS; Bannerji R
Leuk Lymphoma; 2005 Apr; 46(4):635-7. PubMed ID: 16019499
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia.
Laurenti L; Tarnani M; Efremov DG; Chiusolo P; De Padua L; Sica S; Leone G
Leukemia; 2007 Aug; 21(8):1819-21; author reply 1821. PubMed ID: 17443222
[No Abstract] [Full Text] [Related]
14. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
Lozanski G; Heerema NA; Flinn IW; Smith L; Harbison J; Webb J; Moran M; Lucas M; Lin T; Hackbarth ML; Proffitt JH; Lucas D; Grever MR; Byrd JC
Blood; 2004 May; 103(9):3278-81. PubMed ID: 14726385
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil.
Prescrire Int; 2009 Apr; 18(100):60. PubMed ID: 19585719
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab.
Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
[No Abstract] [Full Text] [Related]
17. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia.
Anoop P; Wotherspoon A; Matutes E
Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308
[No Abstract] [Full Text] [Related]
18. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
Demko S; Summers J; Keegan P; Pazdur R
Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
[TBL] [Abstract][Full Text] [Related]
19. A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction.
Cencini E; Sozzi E; Sicuranza A; Fabbri A; Raspadori D; Lauria F; Forconi F
Br J Haematol; 2011 Jul; 154(2):271-4. PubMed ID: 21521181
[No Abstract] [Full Text] [Related]
20. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
Thompson CA
Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
[No Abstract] [Full Text] [Related]
[Next] [New Search]
